Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. JANX
JANX logo

JANX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Janux Therapeutics Inc (JANX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
14.590
1 Day change
-1.02%
52 Week Range
35.340
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

JANX is not a strong buy right now for a beginner long-term investor, even with a $50,000-$100,000 budget. The pre-market setup is constructive and the stock is near a key resistance area, but the overall picture is mixed: momentum is improving, yet analyst targets have been cut repeatedly, hedge funds are selling, and the company still lacks a clear near-term fundamental catalyst. If the investor is impatient and wants to act now, I would still rate it as HOLD rather than BUY.

Technical Analysis

MACD is positive and expanding, RSI is moderately elevated, and price is testing resistance around 14.752. This supports a short-term bounce setup but not a high-conviction long-term breakout.

Options Data

Neutral
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
5

Positive Catalysts

  • Ongoing clinical work on JANX007, JANX014, and JANX011; low expectations after prior selloff; continued bullish long-term analyst coverage from several firms.

Neutral/Negative Catalysts

  • Repeated analyst target cuts, hedge fund selling, discontinued JANX008, delayed JANX007 data timeline, and no major positive news catalyst today.

Financial Performance

Latest quarter details were not available in the provided snapshot.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Consensus remains mixed: bulls still like the platform, but the target cuts and downgrades show reduced confidence in near-term upside.

Wall Street analysts forecast JANX stock price to rise
16 Analyst Rating
Wall Street analysts forecast JANX stock price to rise
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.740
sliders
Low
25
Averages
55.25
High
150
Current: 14.740
sliders
Low
25
Averages
55.25
High
150
Evercore ISI
Outperform
to
NULL
downgrade
$23 -> $22
AI Analysis
2026-05-11
Reason
Evercore ISI
Price Target
$23 -> $22
AI Analysis
2026-05-11
downgrade
Outperform
to
NULL
Reason
Evercore ISI lowered the firm's price target on Janux Therapeutics to $22 from $23 and keeps an Outperform rating on the shares.
Wedbush
Outperform
to
NULL
downgrade
$45 -> $36
2026-05-08
Reason
Wedbush
Price Target
$45 -> $36
2026-05-08
downgrade
Outperform
to
NULL
Reason
Wedbush lowered the firm's price target on Janux Therapeutics to $36 from $45 and keeps an Outperform rating on the shares following quarterly results. The firm notes ANX-007 continues to be investigated in taxane-naive mCRPC, with a recent expansion arm combining the PSMA-targeted TRACTr with darolutamide currently underway. Beyond JANX-007, the company is also advancing next generation PSMA-TRACTr JANX014, with a initial clinical development now underway. Finally, Wedbush looks forward to the continued development of preclinical assets, including PSMA-targeted TRACIr JANX013, which is anticipated to enter clinical trials in the second half of 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for JANX
Unlock Now

People Also Watch